EA201591891A1 - Пептидное соединение - Google Patents
Пептидное соединениеInfo
- Publication number
- EA201591891A1 EA201591891A1 EA201591891A EA201591891A EA201591891A1 EA 201591891 A1 EA201591891 A1 EA 201591891A1 EA 201591891 A EA201591891 A EA 201591891A EA 201591891 A EA201591891 A EA 201591891A EA 201591891 A1 EA201591891 A1 EA 201591891A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peptide
- peptide connection
- receptors
- peptide compound
- drug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
Настоящее изобретение относится к новому пептидному соединению, обладающему действием активации рецепторов GLP-1 и рецепторов GIP, и к применению пептидного соединения в качестве лекарственного средства. В частности, предусматриваются пептид, содержащий частичную последовательность, соответствующую формуле (I), или его соль и лекарственное средство, содержащее их.где каждый символ является таким, как определено в настоящем описании.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013111893 | 2013-05-28 | ||
PCT/JP2014/002772 WO2014192284A1 (en) | 2013-05-28 | 2014-05-27 | Peptide compound |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201591891A1 true EA201591891A1 (ru) | 2016-01-29 |
EA035813B1 EA035813B1 (ru) | 2020-08-14 |
Family
ID=50942304
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090593A EA202090593A3 (ru) | 2013-05-28 | 2014-05-27 | Пептидное соединение |
EA201591891A EA035813B1 (ru) | 2013-05-28 | 2014-05-27 | Пептид-коагонист рецептора glp-1 и рецептора gip и его применение для профилактики или лечения ожирения или диабета у млекопитающего |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090593A EA202090593A3 (ru) | 2013-05-28 | 2014-05-27 | Пептидное соединение |
Country Status (36)
Country | Link |
---|---|
US (2) | US10087229B2 (ru) |
EP (1) | EP3004155B1 (ru) |
JP (2) | JP6429799B2 (ru) |
KR (1) | KR102229051B1 (ru) |
CN (1) | CN105209485B (ru) |
AP (1) | AP2015008781A0 (ru) |
AR (1) | AR096440A1 (ru) |
AU (1) | AU2014272500B2 (ru) |
CA (1) | CA2908581C (ru) |
CL (1) | CL2015003031A1 (ru) |
CY (1) | CY1124790T1 (ru) |
DK (1) | DK3004155T3 (ru) |
DO (1) | DOP2015000261A (ru) |
EA (2) | EA202090593A3 (ru) |
EC (1) | ECSP15044389A (ru) |
ES (1) | ES2900744T3 (ru) |
GE (1) | GEP201706762B (ru) |
HK (1) | HK1216757A1 (ru) |
HR (1) | HRP20212014T1 (ru) |
HU (1) | HUE057361T2 (ru) |
IL (1) | IL242005B (ru) |
LT (1) | LT3004155T (ru) |
MA (1) | MA38472B1 (ru) |
MX (2) | MX2015015464A (ru) |
MY (1) | MY172744A (ru) |
PE (1) | PE20151770A1 (ru) |
PH (1) | PH12015502391A1 (ru) |
PL (1) | PL3004155T3 (ru) |
PT (1) | PT3004155T (ru) |
SG (1) | SG11201507934PA (ru) |
SI (1) | SI3004155T1 (ru) |
TN (1) | TN2015000451A1 (ru) |
TW (1) | TWI638831B (ru) |
UA (1) | UA118558C2 (ru) |
UY (1) | UY35589A (ru) |
WO (1) | WO2014192284A1 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
CN104846061A (zh) * | 2015-05-07 | 2015-08-19 | 中国药科大学 | 一种glp-1受体激动剂的受体亲和力测定方法 |
CN105388239B (zh) * | 2015-12-18 | 2018-01-05 | 兆科药业(合肥)有限公司 | 一种多肽固相合成的监测方法 |
EP3467106A4 (en) | 2016-05-24 | 2020-02-26 | Takeda Pharmaceutical Company Limited | PEPTIDE COMPOUND |
WO2018104263A1 (en) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
JOP20180028A1 (ar) * | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
BR112020014596A2 (pt) * | 2018-01-23 | 2020-12-08 | Gila Therapeutics, Inc. | Formulações, composições e métodos farmacêuticos de peptídeo yy |
PE20210473A1 (es) | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
CN110818771B (zh) * | 2018-08-14 | 2023-01-17 | 陈铭 | 使用氨基酸离子液体的羰基硫介导多肽合成 |
JP2022503793A (ja) * | 2018-09-24 | 2022-01-12 | 武田薬品工業株式会社 | Gip受容体アゴニストペプチド化合物及びその使用 |
US20220016215A1 (en) * | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
CN114269775A (zh) * | 2019-08-19 | 2022-04-01 | 伊莱利利公司 | 肠促胰岛素类似物的制备方法 |
US20230000950A1 (en) | 2019-10-04 | 2023-01-05 | Hanmi Pharm. Co., Ltd. | Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same |
CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
IL296592A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | One-day doses of gip receptor agonistic peptides and their uses |
CN116157414A (zh) | 2020-07-22 | 2023-05-23 | 诺和诺德股份有限公司 | Glp-1和gip受体共激动剂 |
BR112023000270A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
EP4345105A1 (en) | 2021-06-01 | 2024-04-03 | Nanjing Zhine Medicine Technology Co., Ltd. | Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
CN117402219A (zh) * | 2022-07-13 | 2024-01-16 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
WO2024059674A1 (en) | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Gip and glp-1 dual agonist compounds |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA65549C2 (ru) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением |
AU4863797A (en) | 1996-11-12 | 1998-06-03 | Novo Nordisk A/S | Use of glp-1 peptides |
AU3087599A (en) | 1998-03-19 | 1999-10-11 | Bionebraska, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
EP1100530B1 (en) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In-vitro stimulation of beta cell proliferation |
HUP0104579A3 (en) | 1998-12-07 | 2002-05-28 | Univ Tulane | Glp-1 analogues, pharmaceutical compositions comprising thereof and their use |
US20030157107A1 (en) | 2000-05-16 | 2003-08-21 | Kazumasa Miyawaki | Agents for preventing or ameliorating insulin resistance and/or obesity |
ES2327328T3 (es) | 2002-07-04 | 2009-10-28 | Zealand Pharma A/S | Glp-1 y procedimientos para el tratamiento de la diabetes. |
EP1711523B1 (en) | 2003-12-16 | 2012-10-10 | Ipsen Pharma | Analogues of glp-1 |
WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
EA011653B1 (ru) | 2005-02-11 | 2009-04-28 | Амилин Фармасьютикалз, Инк. | Аналоги и гибридные полипептиды gip с избираемыми свойствами |
WO2006136374A2 (en) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells |
AU2007272954A1 (en) | 2006-07-11 | 2008-01-17 | Harkness Pharmaceuticals, Inc. | Methods of treating obesity using satiety factors |
JP5399244B2 (ja) | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
TWI430806B (zh) | 2006-09-13 | 2014-03-21 | Smithkline Beecham Corp | 用於投與長效降血糖藥劑之方法 |
EP1972349A1 (en) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
US8710002B2 (en) | 2007-11-23 | 2014-04-29 | Michael Rothkopf | Methods of enhancing diabetes resolution |
JP6108659B2 (ja) | 2008-06-17 | 2017-04-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 代謝疾患および肥満の治療のためのgipに基づいた混合アゴニスト |
KR101593158B1 (ko) | 2008-08-07 | 2016-02-12 | 입센 파마 에스.에이.에스. | N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체 |
PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
CN102459325B (zh) | 2009-06-16 | 2015-03-25 | 印第安纳大学科技研究有限公司 | 胃抑胜肽受体活化的胰高血糖素化合物 |
WO2011002066A1 (ja) | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | ペプチド及びその用途 |
KR20120123443A (ko) * | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트 |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
JP2014501762A (ja) | 2010-12-22 | 2014-01-23 | マルケイディア バイオテック, インコーポレイテッド | Gipおよびglp−1受容体活性グルカゴン系ペプチドにより代謝障害および肥満を治療するための方法 |
EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
EP2718317B1 (en) * | 2011-06-10 | 2018-11-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
MX341324B (es) | 2011-06-10 | 2016-08-16 | Novo Nordisk As | Polipeptidos. |
US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
CN107266558A (zh) | 2011-09-06 | 2017-10-20 | 诺沃—诺迪斯克有限公司 | Glp‑1衍生物 |
EP2830646B1 (en) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
EA028665B1 (ru) | 2012-05-03 | 2017-12-29 | Зилэнд Фарма А/С | Соединения - двойные агонисты gip-glp-1 и способы |
WO2013167454A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
US20150182461A1 (en) | 2012-06-19 | 2015-07-02 | Massachussets Institute Of Technology | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices |
EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
WO2013192130A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting gip receptor activity |
WO2014096179A1 (en) | 2012-12-19 | 2014-06-26 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
US9714277B2 (en) | 2013-03-14 | 2017-07-25 | Medimmune Limited | Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity |
DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2014
- 2014-05-27 DK DK14729976.2T patent/DK3004155T3/da active
- 2014-05-27 LT LTEPPCT/JP2014/002772T patent/LT3004155T/lt unknown
- 2014-05-27 SG SG11201507934PA patent/SG11201507934PA/en unknown
- 2014-05-27 US US14/780,579 patent/US10087229B2/en active Active
- 2014-05-27 GE GEAP201413984A patent/GEP201706762B/en unknown
- 2014-05-27 WO PCT/JP2014/002772 patent/WO2014192284A1/en active Application Filing
- 2014-05-27 JP JP2015555470A patent/JP6429799B2/ja active Active
- 2014-05-27 EA EA202090593A patent/EA202090593A3/ru unknown
- 2014-05-27 CA CA2908581A patent/CA2908581C/en active Active
- 2014-05-27 TN TN2015000451A patent/TN2015000451A1/en unknown
- 2014-05-27 CN CN201480026613.0A patent/CN105209485B/zh active Active
- 2014-05-27 MA MA38472A patent/MA38472B1/fr unknown
- 2014-05-27 EA EA201591891A patent/EA035813B1/ru unknown
- 2014-05-27 AR ARP140102090A patent/AR096440A1/es unknown
- 2014-05-27 HU HUE14729976A patent/HUE057361T2/hu unknown
- 2014-05-27 PT PT147299762T patent/PT3004155T/pt unknown
- 2014-05-27 SI SI201431933T patent/SI3004155T1/sl unknown
- 2014-05-27 MX MX2015015464A patent/MX2015015464A/es active IP Right Grant
- 2014-05-27 ES ES14729976T patent/ES2900744T3/es active Active
- 2014-05-27 HR HRP20212014TT patent/HRP20212014T1/hr unknown
- 2014-05-27 US US14/287,514 patent/US9200051B2/en active Active
- 2014-05-27 UY UY0001035589A patent/UY35589A/es not_active Application Discontinuation
- 2014-05-27 TW TW103118374A patent/TWI638831B/zh active
- 2014-05-27 PE PE2015002124A patent/PE20151770A1/es unknown
- 2014-05-27 PL PL14729976T patent/PL3004155T3/pl unknown
- 2014-05-27 KR KR1020157032121A patent/KR102229051B1/ko active IP Right Grant
- 2014-05-27 AU AU2014272500A patent/AU2014272500B2/en active Active
- 2014-05-27 UA UAA201510946A patent/UA118558C2/uk unknown
- 2014-05-27 EP EP14729976.2A patent/EP3004155B1/en active Active
- 2014-05-27 MY MYPI2015703438A patent/MY172744A/en unknown
- 2014-05-27 AP AP2015008781A patent/AP2015008781A0/xx unknown
-
2015
- 2015-10-11 IL IL242005A patent/IL242005B/en active IP Right Grant
- 2015-10-13 CL CL2015003031A patent/CL2015003031A1/es unknown
- 2015-10-14 PH PH12015502391A patent/PH12015502391A1/en unknown
- 2015-10-15 DO DO2015000261A patent/DOP2015000261A/es unknown
- 2015-10-21 EC ECIEPI201544389A patent/ECSP15044389A/es unknown
- 2015-11-06 MX MX2019010531A patent/MX2019010531A/es unknown
-
2016
- 2016-04-28 HK HK16104856.7A patent/HK1216757A1/zh unknown
-
2018
- 2018-06-12 JP JP2018111494A patent/JP6570705B2/ja active Active
-
2021
- 2021-12-15 CY CY20211101100T patent/CY1124790T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591891A1 (ru) | Пептидное соединение | |
EA201992327A1 (ru) | Пептид, активирующий рецептор гип | |
EA201591624A1 (ru) | Новые производные пиразола | |
EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
EA201890239A2 (ru) | Фумараты как пролекарства и их применение при лечении различных заболеваний | |
EA201591527A1 (ru) | Новые производные пиридина | |
EA201690629A1 (ru) | Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip | |
EA201690046A1 (ru) | Композиция зародышеобразователя и термопластичная полимерная композиция, включающая такую композицию зародышеобразователя | |
UY33541A (es) | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas | |
EA201591064A1 (ru) | Новые производные пиридина | |
EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201300388A1 (ru) | Соединения замещенного бензамида | |
EA201690478A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛ[4,5-d]ПИРИМИДИНА | |
EA201400753A1 (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
EA201490596A1 (ru) | Новые производные дигидрохинолин-2-она | |
EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
EA201591567A1 (ru) | Новые производные пиридина | |
EA201590854A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
EA201692548A1 (ru) | Минеральные аминокислотные комплексы активных веществ | |
EA201490037A1 (ru) | Антагонисты trpv4 | |
EA201690894A1 (ru) | Феноксиэтилы | |
EA201590688A1 (ru) | Производные n-проп-2-инилкарбоксамида и их применение в качестве антагонистов trpa1 | |
EA201500931A1 (ru) | Производные пиридин-4-ила | |
EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 |